Vivos Inc. reported its financial results for the first quarter of 2026, revealing a net loss of $1.18 million, compared to a net loss of $834,696 in the same period of 2025. The company's revenue increased to $36,068, up from $26,748 year-over-year, primarily driven by its IsoPet® therapies. However, the cost of goods sold also rose to $44,086 from $35,831, resulting in a gross loss of $8,018, an improvement from the previous gross loss of $9,083. Operating expenses decreased significantly to $537,474 from $854,449, largely due to reduced professional fees and research and development costs.
In terms of operational metrics, Vivos Inc. has made strategic advancements, including the establishment of Vivos Scientific India LLP in September 2025, aimed at expanding its manufacturing capabilities and pursuing regulatory approvals for human therapies in India. The company has also focused on enhancing its leadership team, appointing Brad Allan Weeks as President and David J. Swanberg as Chief Operating Officer to support its growth initiatives. As of March 31, 2026, Vivos had 17 certified regional clinics for its IsoPet® therapy, which reported a 1,200% year-over-year increase in administered therapies in 2025.
The company’s cash position improved to $2.53 million as of March 31, 2026, compared to $1.56 million at the end of 2025. This increase was attributed to financing activities, including proceeds from the Regulation A+ offerings. However, Vivos Inc. continues to face liquidity challenges, requiring approximately $3 million annually to maintain operations. The company anticipates needing an additional $9 million over the next three years to fund FDA approval processes, clinical trials, and the establishment of production facilities.
Looking ahead, Vivos Inc. aims to achieve breakeven in its Animal Therapy Division by 2026, supported by ongoing profitability initiatives and clinic expansions. The company is also preparing for a resubmission of its Investigational Device Exemption (IDE) application to the FDA, which is critical for advancing its RadioGel™ human therapy product. The management remains cautious about the future, emphasizing the need for additional capital to sustain operations and support its strategic objectives.
About VIVOS INC
Vivos Inc. develops precision radionuclide therapy devices, primarily RadioGel, for treating non-resectable tumors in humans and animals. Its core focus includes FDA-approved cancer treatments, veterinary oncology solutions under the IsoPet brand, and innovative isotope technologies. The company leverages strategic partnerships, proprietary patents, and clinical trials to deliver targeted, minimally invasive therapies with competitive advantages in safety, efficacy, and regulatory progress.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.